DARPA Awards $11M Prime Contract to NRx Defense for Robotic TMS Depression Trial
NRXP sits 84% above its 52-week low of $1.62.
Summary
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals, has been awarded an initial $11.18 million DARPA prime contract to evaluate robotic magnetic stimulation combined with NRX-101 for treatment-resistant depression. The SPARC-TMS trial has received FDA approval and will begin enrolling patients at Harvard's McLean Hospital, Arizona State University, and HOPE Therapeutics, with military hospitals affiliated. This is a material step forward from the July 8-K, which only noted DARPA selection to negotiate a potential award. The contract provides non-dilutive funding and validates the company's defense-focused strategy, while the trial could serve as an FDA registration study for NRX-101 in a much larger patient population. The company remains in a going-concern position with a $16.5 million Q2 net loss, so this award meaningfully supports its cash runway. Watch for enrollment updates and any additional DARPA funding tranches.
At the time of this announcement, NRXP was trading at $2.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.4M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.